Dmitry V. Vlodavets

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 041.

Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 041.

Journal: Journal of comparative effectiveness research
Published: March 25, 2026

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

Journal: The Lancet. Child & adolescent health
Published: January 28, 2026

Pharmacoeconomic evaluation of spinal muscular atrophy therapy in patients with four SMN2 copies diagnosed through newborn screening

Pharmacoeconomic evaluation of spinal muscular atrophy therapy in patients with four SMN2 copies diagnosed through newborn screening

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 12, 2026

The Duchenne muscular dystrophy continuum: a modified staging classification

The Duchenne muscular dystrophy continuum: a modified staging classification

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: October 06, 2025

Balanced Translocations Involving the DMD Gene as a Cause of Muscular Dystrophy in Female Children: A Description of Three Cases.

Balanced Translocations Involving the DMD Gene as a Cause of Muscular Dystrophy in Female Children: A Description of Three Cases.

Journal: International journal of molecular sciences
Published: September 05, 2025

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.

Journal: Journal of comparative effectiveness research
Published: August 22, 2025

Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies.

Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies.

Journal: Annals of clinical and translational neurology
Published: August 22, 2025

Risdiplam in Presymptomatic Spinal Muscular Atrophy.

Risdiplam in Presymptomatic Spinal Muscular Atrophy.

Journal: The New England journal of medicine
Published: August 13, 2025

Natural history of spinal muscular atrophy type I

Natural history of spinal muscular atrophy type I

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: December 18, 2024

Risdiplam for the treatment of spinal muscular atrophy

Risdiplam for the treatment of spinal muscular atrophy

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: March 11, 2024

Sleep disorders and fatigue in patients with different forms of myotonic dystrophy type 1

Sleep disorders and fatigue in patients with different forms of myotonic dystrophy type 1

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: September 01, 2023

Pilot Program of Newborn Screening for 5q Spinal Muscular Atrophy in the Russian Federation.

Pilot Program of Newborn Screening for 5q Spinal Muscular Atrophy in the Russian Federation.

Journal: International journal of neonatal screening
Published: December 01, 2022
Showing 1-12 of 18

Last Updated: 09/26/2026